Marcel P M Stokkel
Overview
Explore the profile of Marcel P M Stokkel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
117
Citations
1724
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Stokkel M, Owers E
Eur J Nucl Med Mol Imaging
. 2023 Apr;
50(8):2231-2235.
PMID: 37052628
No abstract available.
12.
Donswijk M, Piek M, Cheung Z, Wondergem M, Stokkel M, de Boer J, et al.
Eur Radiol
. 2023 Mar;
33(5):3377-3385.
PMID: 36892644
Objective: To investigate the incidences of prostate-specific membrane antigen (PSMA) thyroid incidentaloma (PTI) using different methods to define PTI, to compare the incidence of PTI among different PSMA PET tracers,...
13.
Veerman C, Siebinga H, de Vries-Huizing D, Tesselaar M, Hendrikx J, Stokkel M, et al.
Eur J Nucl Med Mol Imaging
. 2023 Jan;
50(5):1434-1441.
PMID: 36598536
Purpose: According to IAEA/EANM/SNMMI guidelines, long-acting somatostatin analogues (LA-SSAs) should be discontinued 4-6 weeks prior to peptide receptor radionuclide therapy (PRRT) to prevent somatostatin receptor saturation. The aim of this...
14.
Siebinga H, Veerman C, de Wit-van der Veen L, Stokkel M, Hendrikx J, Aalbersberg E
EJNMMI Res
. 2022 Dec;
12(1):74.
PMID: 36515683
Background: Receptor saturation during peptide receptor radionuclide therapy (PRRT) could result in altered [Lu]Lu-HA-DOTATATE uptake in tumors and organs. Therefore, receptor expression status and effects of different (unlabeled) administered peptide...
15.
Donswijk M, Wondergem M, de Wit-van der Veen L, Bruin N, van Leeuwen P, van der Poel H, et al.
EJNMMI Res
. 2022 Jul;
12(1):42.
PMID: 35895129
Background: High urinary activity in urinary bladder and ureters may hamper interpretation of prostate cancer and regional nodal metastases in prostate-specific membrane antigen (PSMA) PET/CT. The goal of this study...
16.
Aalbersberg E, de Vries-Huizing D, Tesselaar M, Stokkel M, Versleijen M
Cancer Imaging
. 2022 Jun;
22(1):29.
PMID: 35715867
Aim: The aim of this study was to evaluate the clinical utility of SPECT/CT (imaging of uptake in tumor lesions and additional findings) and the additional value of planar imaging...
17.
van der Hiel B, Blankenstein S, Aalbersberg E, Wondergem M, Stokkel M, van de Wiel B, et al.
Clin Nucl Med
. 2022 Apr;
47(7):583-589.
PMID: 35452004
Purpose: The aim of this study was to investigate whether 18F-FDG PET/CT can predict histopathological response or recurrence in BRAF-mutated unresectable locally advanced stage III melanoma treated with neoadjuvant BRAF/MEK...
18.
van Loevezijn A, van der Noordaa M, Stokkel M, van Werkhoven E, Groen E, Loo C, et al.
Breast Cancer Res Treat
. 2022 Mar;
193(1):37-48.
PMID: 35239072
Purpose: In clinically node-positive (cN+) breast cancer patients, evidence supporting response-guided treatment after neoadjuvant systemic therapy (NST) instead of axillary lymph node dissection (ALND) is increasing, but follow-up results are...
19.
de Vries-Huizing D, Versleijen M, Sinaasappel M, Walraven I, Geluk-Jonker M, Tesselaar M, et al.
PLoS One
. 2021 Nov;
16(11):e0260073.
PMID: 34793530
Background: Mainly severe (CTCAE grade 3-4) haematotoxicity during peptide receptor radionuclide therapy (PRRT) is reported in literature due to major clinical impact, however moderate (CTCAE grade 2) haematotoxicity is common...
20.
van Loevezijn A, Stokkel M, Donswijk M, van Werkhoven E, van der Noordaa M, van Duijnhoven F, et al.
EJNMMI Res
. 2021 Aug;
11(1):78.
PMID: 34417932
Purpose: Axillary staging before neoadjuvant systemic therapy in clinically node-positive breast cancer patients with tailored axillary treatment according to the Marking Axillary lymph nodes with radioactive iodine seeds (MARI)-protocol, a...